Compare GBTG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBTG | LEGN |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.9B |
| IPO Year | 2020 | 2020 |
| Metric | GBTG | LEGN |
|---|---|---|
| Price | $9.40 | $29.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $8.92 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 3.2M | 3.2M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 173.33 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $2,718,000,000.00 | N/A |
| Revenue This Year | $21.78 | $42.68 |
| Revenue Next Year | $4.29 | $30.52 |
| P/E Ratio | $94.00 | ★ N/A |
| Revenue Growth | ★ 12.17 | N/A |
| 52 Week Low | $4.96 | $16.24 |
| 52 Week High | $9.54 | $45.30 |
| Indicator | GBTG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.64 | 49.49 |
| Support Level | $9.33 | $24.94 |
| Resistance Level | $9.46 | $33.90 |
| Average True Range (ATR) | 0.04 | 1.66 |
| MACD | -0.06 | -0.60 |
| Stochastic Oscillator | 68.18 | 26.87 |
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.